Summit Therapeutics (SMMT) stock has surged significantly today, continuing a trend from earlier this week due to the positive results from its Phase III trial of Ivonescimab, a promising lung cancer therapy. The trial showed that Ivonescimab reduced disease progression by 49% compared to Merck's Keytruda, which is a leading treatment in this space. This breakthrough suggests that Ivonescimab could potentially become a more effective treatment, leading to a lot of investor interest. Multiple analysts have raised their price targets, further fueling the stock's upward momentum()()().
